In short: The Fed understands all the reasons to slow down and then end its $85 billion of monthly bond purchases ��the fear that it is distorting markets, and that the sheer size of its portfolio may prove unwieldy as the economy improves. But ...
Fed minutes: Policymakers see tapering 'in coming months'
Full text: Minutes of the Fed's Oct. 29-30 meeting
The Fed also noted that only one member of the committee that sets monetary policy thought the economy has improved enough to begin easing off purchases, which pump money into the economy and especially into the housing market. The minutes released Wednesday show the other members worried about everything from the slowdown induced by federal spending cuts to the slowdown in housing that began virtually immediately after the Fed began hinting at tightening policy in May and June.
Top 5 Internet Companies To Invest In Right Now: Athersys Inc.(ATHX)
Athersys, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutic products in various disease areas in the United States. Its clinical development programs are focused on treating cardiovascular disease, neurological conditions, inflammatory and immune disorders, and other conditions. Its product pipeline includes MultiStem, a novel allogeneic approach to stem cell therapy and regenerative medicine for treating a range of diseases. The company is also involved in the development of novel small molecule compounds for applications in indications, such as obesity and other areas, including the treatment of neurological conditions, and for the modulation of stem cells or related applications in the regenerative medicine area. It has product co-development collaboration with Pfizer Inc. to develop and commercialize MultiStem to treat inflammatory bowel disease for the worldwide market; Angiotech Pharmaceuticals, Inc. to develop and commerciali ze MultiStem to treat certain cardiovascular diseases, such as acute myocardial infarction; and RTI Biologics, Inc. to develop and commercialize biologic implants for certain orthopedic applications in the bone graft substitutes market. The company was founded in 1995 and is based in Cleveland, Ohio.
Advisors' Opinion:- [By Roberto Pedone]
Another under-$10 biotechnology player that's starting to trend within range of triggering a big breakout trade is Athersys (ATHX), which focuses on the research and development activities in the field of regenerative medicine. This stock has been destroyed by the bears over the last six months, with shares off sharply by 62%.
If you look at the chart for Athersys, you'll see that this stock has been downtrending badly for the last two months and change, with shares moving lower from its high of $1.99 to its recent low of $1.31 a share. During that downtrend, shares of ATHX have been making mostly lower highs and lower lows, which is bearish technical price action. That said, shares of ATHX are now starting to bounce off some near-term support at $1.31 and it's now starting to trend within range of triggering a big breakout trade above some near-term overhead resistance levels.
Market players should now look for long-biased trades in ATHX if it manages to break out above some near-term overhead resistance levels at $1.40 to $1.49 a share and then back above its 50-day moving average of $1.52 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 384,325 shares. If that breakout hits soon, then ATHX will set up to re-test or possibly take out its next major overhead resistance levels at $1.70 to $1.78 a share, or even $1.99 a share.
Traders can look to buy ATHX off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support at $1.31 a share. One can also buy ATHX off strength once it starts to bust above those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
Read More: Warren Buffett's Top 10 Dividend Stocks
- [By Sean Williams]
What: Shares of Athersys (NASDAQ: ATHX ) , a clinical-stage biotechnology company focused on regenerative medicine, advanced as much as 10% after announcing that it had been granted three new patents for its stem cell and regenerative technologies in Japan.
- [By Lisa Levin]
Athersys (NASDAQ: ATHX) shares fell 56.04% to reach a new 52-week low of $1.20 on failed trial results for ulcerative colitis.
Posted-In: 52-Week LowsNews Movers & Shakers Intraday Update Markets
Top 5 Prefered Stocks To Invest In Right Now: Prosensa Holding NV (RNA)
Prosensa Holding N.V., formerly Prosensa Holding B.V., is a biotechnology company engaged in the discovery and development of ribonucleic acid-modulating (RNA)-modulating, therapeutics for the treatment of genetic disorders. The Company�� primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy, myotonic dystrophy and Huntington�� disease. The Company�� clinical portfolio of RNA-based product candidates is focused on the treatment of Duchenne muscular dystrophy (DMD). The Company�� platform technology allows the development of RNA-modulating therapeutics that either interferes with splicing (exon skipping, exon inclusion, or splice mutation correction), remove mutant RNA, or block RNA expression, for different indications.
DMD is a rare, severe muscle wasting disease that occurs in up to 1 in 3,500 male births. It is commonly diagnosed between the ages of three to five, when boys begin to show signs of impaired motor development. PRO044, the Company�� product candidate, addresses a separate sub-population of DMD patients. The Company developed PRO044 using its exon-skipping technology to generate a product candidate with the same mechanism of action that is used by drisapersen.
Advisors' Opinion:- [By John Udovich]
Recent news surrounding small cap biotech stocks like�Xencor Inc (NASDAQ: XNCR), Prosensa Holding NV (NASDAQ: RNA),�Puma Biotechnology Inc (NYSE: PBYI),�Geron Corporation (NASDAQ: GERN)
and TNI BioTech Inc (OTCQB: TNIB) show that while the sector and appetite for biotech�IPOs may have cooled, lottery tickets can still be found or occur in the sector. Just consider the following recent news or trends: - [By Monica Gerson]
Prosensa Holding NV (NASDAQ: RNA) soared 25.89% to $8.51 in the pre-market trading after the company reported 48-week data from Phase 2 placebo-controlled study of drisapersen in 51 DMD boys.
- [By John Udovich]
It should also be mentioned that earlier in the week, GlaxoSmithKline plc (NYSE: GSK) returned full rights of Duchenne muscular dystrophy drug drisapersen to their partner�Prosensa Holding NV (NASDAQ: RNA) and that news sent shares down 12.48% on�Monday. Moreover,�Prosensa Holding also sank some 70% last fall when Drisapersen failed a phase 3 trial by missing a primary endpoint measuring for how far patients could walk over the course of six minutes (the improvement�wasn't significantly better than the placebo).�However, Prosensa Holding also rose 24.37% yesterday after announcing�initial findings from further analyses from the aggregate data for drisapersen, with the CEO saying:
- [By Keith Speights]
Successful launch
You couldn't even buy stock in Prosensa (NASDAQ: RNA ) just a few weeks ago. The biotech launched its IPO on June 28. To say that launch has gone successfully is an understatement. Shares are now more than double the IPO price and climbed 41% this week.
Top 5 Prefered Stocks To Invest In Right Now: Cubist Pharmaceuticals Inc.(CBST)
Cubist Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. The company markets CUBICIN (daptomycin for injection), a once-daily, bactericidal, intravenous, antibiotic with activity against gram-positive organisms, including methicillin-resistant staphylococcus aureus. Its clinical development product pipeline consists of CXA-201, which is in the phase III clinical trial for patients with complicated urinary tract infections; and in phase II clinical trial for patients with complicated abdominal infections. The company is also developing CXA-201 for the treatment of hospital acquired pneumonia. In addition, its product under development comprises CB-183,315, an oral, bactericidal lipopeptide with in vitro bactericidal activity against C. difficile, for the treatment of clostridium difficile-associated diarrhea (CDAD). Further , the company?s pre-clinical programs include therapies to treat various bacterial infections and agents to treat acute pain. Additionally, it promotes MERREM I.V. (meropenem for injection), a carbapenem class intravenous antibiotic, in the United States under a commercial services agreement with AstraZeneca Pharmaceuticals, LP; and DIFICID as the treatment for CDAD in adults under the co-promotion agreement with Optimer Pharmaceuticals, Inc. The company also has collaborations with Forma Therapeutics, Inc. to discover and develop antibacterial compounds; an agreement with the Broad Institute to transform natural products discovery; a collaboration with Hydra Biosciences, Inc., to develop ion channel drugs; and a collaboration agreement with Alnylam Pharmaceuticals, Inc., for the development and commercialization of Alnylam's RNAi therapeutics as a therapy for the treatment of respiratory syncytial virus. The company was founded in 1992 and is headquartered in Lexington, Mas sachusetts.
Advisors' Opinion:- [By Rich Bieglmeier]
[Related -Cubist Pharmaceuticals Inc. (CBST): All-Time Highs On The Horizon?]
The FDA has accepted the Company's New Drug Application (NDA) for its investigational antibiotic tedizolid phosphate (TR-701) with Priority Review. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of June 20, 2014. Cubist is seeking FDA approval of tedizolid for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
- [By Victor Selva]
Forest Laboratories has a current ratio of 2.69% which is higher than the ones registered by Endo International Plc (ENDP), Valeant Pharmaceuticals International (VRX) and Cubist Pharmaceuticals Inc. (CBST). For investors looking for a higher ROE, Allergan Inc. (AGN) and Actelion Ltd. (ATLN.VX) are good options.
Top 5 Prefered Stocks To Invest In Right Now: Horsehead Holding Corp.(ZINC)
Horsehead Holding Corp., together with its subsidiaries, produces and sells specialty zinc and zinc-based products in North America. The company?s products include PW zinc metal, which is used to provide a protective coating to various fabricated products, including pipe and guard rails, heat exchangers, and telecommunications towers, as well as for the production of brass; and SSHG zinc metal that is used as feed for the manufacture of high-purity zinc powder and zinc alloys. It also offers zinc oxide for the production of tire and rubber products, chemicals, ceramics, plastics, paints, lubricating oils, and pharmaceuticals. In addition, the company recycles electric arc furnace dust, a hazardous waste generated by steel mini-mills. Further, it provides special zinc powders, which are used in general chemical and metallurgical applications, as well as in friction applications, such as brake linings for automobiles; battery grade zinc powders that are used in alkaline, me rcuric oxide, silver oxide, and zinc-air batteries; and copper-based powders, including brass, bronze, and nickel-silver powders, which are used in various applications comprising brazing, infiltrating, and powdered metallurgical hardware, such as lock bodies, valves, and gears. Additionally, the company offers short-line railroad service for the movement of materials. It primarily serves galvanizers and brass producers; alkaline battery industries; and manufacturers of tire and rubber products, lubricating oils, chemicals, paints, ceramics, plastics, and pharmaceuticals. The company was incorporated in 2003 and is based in Pittsburgh, Pennsylvania.
Advisors' Opinion:- [By Jake L'Ecuyer]
Leading and Lagging Sectors
Basic materials shares jumped about 1.72 percent in Monday's trading. Leading the sector was strength from Century Aluminum Co (NASDAQ: CENX) and Horsehead Holding (NASDAQ: ZINC). In trading on Monday, utilities shares dropped by 0.13 percent.
No comments:
Post a Comment